Pre-made Grisnilimab benchmark antibody ( Whole mAb, anti-CD7 therapeutic antibody, Anti-GP40/TP41/Tp40/LEU-9 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Grisnilimab biosimilar, Whole mAb, Anti-CD7 Antibody: Anti-GP40/TP41/Tp40/LEU-9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-254-1mg	1mg	3090
GMP-Bios-ab-254-10mg	10mg	Inquiry
GMP-Bios-ab-254-100mg	100mg	Inquiry
GMP-Bios-ab-254-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Grisnilimab biosimilar, Whole mAb, Anti-CD7 Antibody: Anti-GP40/TP41/Tp40/LEU-9 therapeutic antibody
INN Name	Grisnilimab
Target	CD7
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2a
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	2021
Companies	Xenikos
Conditions Approved	na
Conditions Active	Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease
Conditions Discontinued	na
Development Tech	na